| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 2949- | PL, | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 2953- | PL, | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
| - | in-vitro, | Nor, | NA |
| 2965- | PL, | docx, | Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer |
| - | Analysis, | Var, | NA |
| 2962- | PL, | Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents |
| - | in-vitro, | Nor, | PC12 |
| 2958- | PL, | Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity |
| - | in-vitro, | Oral, | HSC3 |
| 2956- | PL, | Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis |
| - | in-vitro, | PC, | NA |
| 1940- | PL, | Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 1946- | PL, | PI, | Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling |
| - | in-vitro, | Liver, | NA |
| 1947- | PL, | Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | NA |
| 1939- | PL, | Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HUH7 | - | in-vivo, | NA, | NA |
| 1944- | PL, | Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress |
| - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 1951- | PL, | Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation |
| - | in-vitro, | Lung, | A549 |
| 1950- | PL, | Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 |
| 5163- | PLB, | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5162- | PLB, | Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells |
| - | vitro+vivo, | Melanoma, | A172 |
| 5161- | PLB, | Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5159- | PLB, | Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression |
| - | in-vitro, | AML, | K562 |
| 5158- | PLB, | Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells |
| - | in-vitro, | Cerv, | ME-180 |
| 2004- | PLB, | Plumbagin Inhibits Proliferative and Inflammatory Responses of T Cells Independent of ROS Generation But by Modulating Intracellular Thiols |
| - | in-vivo, | Var, | NA |
| 2005- | PLB, | Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) |
| - | in-vivo, | Nor, | EL4 | - | in-vitro, | AML, | Jurkat |
| 2006- | PLB, | Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
| 3916- | PS, | The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study |
| - | Human, | AD, | NA |
| 1986- | PTL, | Modulation of Cell Surface Protein Free Thiols: A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide |
| - | in-vitro, | Var, | NA |
| 1984- | PTL, | Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 1996- | PTL, | Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells |
| - | in-vitro, | CRC, | COLO205 |
| 1989- | PTL, | Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties |
| - | Review, | Var, | NA |
| 1990- | PTL, | Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway |
| - | in-vitro, | AD, | PC12 |
| 1992- | PTL, | Parthenolide induces ROS-dependent cell death in human gastric cancer cell |
| - | in-vitro, | BC, | MGC803 |
| 5032- | PTS, | Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism |
| - | in-vivo, | Melanoma, | NA |
| 4703- | PTS, | RES, | Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review |
| - | in-vivo, | Nor, | NA |
| 4690- | PTS, | immuno, | Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies |
| - | Review, | Var, | NA |
| 4689- | PTS, | Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol |
| - | in-vitro, | Cerv, | HeLa |
| 8606- | PumpSO, | Tamsu, | Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial |
| - | Trial, | BPH, | NA |
| 3343- | QC, | Quercetin, a Flavonoid with Great Pharmacological Capacity |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 3611- | QC, | Quercetin and vitamin C supplementation: effects on lipid profile and muscle damage in male athletes |
| - | Trial, | Nor, | NA |
| 41- | QC, | Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft |
| - | vitro+vivo, | AML, | HL-60 |
| 50- | QC, | Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer |
| - | vitro+vivo, | Ovarian, | A2780S |
| 75- | QC, | ENZ, | Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells |
| - | in-vitro, | Pca, | HEK293 | - | in-vitro, | NA, | 22Rv1 | - | in-vitro, | NA, | C4-2B |
| - | in-vitro, | Pca, | CD44+ | - | in-vitro, | NA, | CD133+ | - | in-vitro, | NA, | PC3 | - | in-vitro, | NA, | LNCaP |
| 4686- | QC, | Quercetin suppresses endometrial cancer stem cells via ERα-mediated inhibition of STAT3 signaling |
| - | in-vitro, | EC, | EMN8 | - | in-vitro, | EC, | EMN21 |
| 5030- | QC, | Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy |
| - | in-vivo, | Nor, | NA |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 6056- | RES, | SeNPs, | A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: Inhibiting amyloid β aggregation and reactive oxygen species formation properties |
| - | Study, | AD, | NA |
| 1511- | RES, | Chemo, | Combination therapy in combating cancer |
| - | Review, | Var, | NA |
| 2567- | RES, | Neuroprotective Effects of Resveratrol in Ischemic Brain Injury |
| - | Review, | Stroke, | NA |
| 2566- | RES, | A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke |
| - | Review, | Stroke, | NA |
| 2442- | RES, | High absorption but very low bioavailability of oral resveratrol in humans |
| - | in-vitro, | Nor, | NA |
| 2441- | RES, | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
| - | Review, | Var, | NA |
| 3087- | RES, | Resveratrol cytotoxicity is energy-dependent |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid